Clario, a provider of clinical trial technologies, has partnered with Mobilise-D consortium to integrate Digital Mobility Outcomes (DMOs) into clinical trials.

The collaboration integrates Mobilise-D's validated algorithms into Clario's Opal wearable sensor system, enabling real-world mobility assessments for patients. This integration allows for more objective, reliable, and accurate measurements of human movement compared to conventional clinical scales, particularly benefiting neuroscience studies, where mobility insights outside clinical settings are crucial.

Clario is implementing these algorithms in a study with multiple sclerosis patients to establish the technical equivalence of its Opal precision motion device. The partnership aims to enhance clinical outcomes by combining mobility performance data from wearable sensors with electronic clinical outcome assessment (eCOA).

Analyst QuickTake: Earlier, in June 2024 , sources indicated that Clario confidentially filed for a US IPO, targeting a valuation of more than USD 10 billion. The valuation is considered aggressive yet plausible, given that it generates an annual revenue of USD 1.1 billion and an EBITDA of ~USD 400 million. However, through partnerships with companies such as Mobilise-D, the company appears to be showcasing its platform’s versatility and ability to enhance clinical outcomes by integrating with various third-party solutions. This would help expand its use cases and increase its potential.